



NDA 21-572/S-038

**SUPPLEMENT APPROVAL**

Cubist Pharmaceuticals, Inc.  
Attention: Jennifer A. Liscouski  
Senior Manager, Regulatory Affairs  
65 Hayden Avenue  
Lexington, MA 02421

Dear Ms. Liscouski:

Please refer to your Supplemental New Drug Application (sNDA) dated June 28, 2011, received, June 30, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cubicin (daptomycin for injection).

This “Prior Approval” supplemental new drug application provides for revisions to Section 12.4 of the labeling text, under “Susceptibility Testing Methods, Quality Control” in Table 10. The broth dilution minimum inhibitory concentration (MIC) range for *Staphylococcus aureus* (ATCC 29213) has been changed from 0.25-1 µg/mL to 0.12-1 µg/mL.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revision listed below:

- Please update reference #2 to the most recent version of this document with the next printing.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior, Regulatory Project Manager, at (301) 796-0702.

Sincerely,

*{See appended electronic signature page}*

Sumathi Nambiar MD MPH  
Deputy Director for Safety  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SUMATHI NAMBIAR  
10/03/2011